+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory and field investigations of bovine myxovirus parainfluenza 3 virus and vaccine. II. Development and appraisal of potency of SF-4 virus vaccine



Laboratory and field investigations of bovine myxovirus parainfluenza 3 virus and vaccine. II. Development and appraisal of potency of SF-4 virus vaccine



Jour Immunol 87(2): 134-138



A potent formalin -killed vaccine was prepared from bovine kidney cultures infected with the SF-4 strain of myxovirus parainfluenza 3 virus. The aqueous vaccine was highly potent for guinea pigs when administered by various routes and regularly evoked the formation of neutralizing, HI and CF antibodies. On the other hand, the aqueous vaccine was of insufficient potency to immunize cattle in the dosage employed. Emulsification of the vaccine with Arlacel A-mineral oil adjuvant effected great enhancement of anti-genic potency. Such material, in proper dosage, evoked high level antibody response in both guinea pigs and bovines. The significance of the findings is discussed.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 024930766

Download citation: RISBibTeXText


Related references

Laboratory and field investigations of bovine Myxovirus parainfluenza 3 virus and vaccine. II. Development and appraisal of potency of SF-4 (shipping fever) virus vaccine. Journal of Immunology 87: 134-138, 1961

Laboratory and field investigations of bovine Myxovirus parainfluenza 3 virus and vaccine. III. Evaluation of an SF-4 (shipping fever) virus vaccine in cattle. Journal of Immunology 87: 139-146, 1961

Laboratory and field investigations of bovine Myxovirus parainfluenza 3 virus and vaccine. I. Properties of the SF-4 (shipping fever) strain of virus. Journal of Immunology 87: 126-133, 1961

Vaccination of beef calves before weaning with a live-virus bovine myxovirus parainfluenza-3 vaccine. American Journal of Veterinary Research 29(7): 1349-1353, 1968

Immunogenicity of a modified-live virus vaccine against bovine viral diarrhea virus types 1 and 2, infectious bovine rhinotracheitis virus, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus when administered intranasally in young calves. Vaccine 28(22): 3784-3792, 2010

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. American Journal of Epidemiology 89(4): 435-448, 1969

Field evaluation of a respiratory syncytial virus vaccine and a tri valent parainfluenza virus vaccine in a pediatric population children. American Journal Of Epidemiology: 449-463, 1969

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. American Journal of Epidemiology 89(4): 449-463, 1969

Experimental and field usage of inactivated bovine virus diarrhea or infectious bovine rhinotracheitis parainfluenza type 3 bovine virus diarrhea vaccine in feedlot cattle. Bovine Practitioner (19): 33-36, 1984

Comparison of single vaccination versus revaccination with a modified-live virus vaccine containing bovine herpesvirus-1, bovine viral diarrhea virus (types 1a and 2a), parainfluenza type 3 virus, and bovine respiratory syncytial virus in the prevention of bovine respiratory disease in cattle. Journal of the American Veterinary Medical Association 235(5): 580-587, 2009

Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus. Vaccine 29(29-30): 4657-4662, 2011

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. Journal of Virology 74(24): 11626-11635, 2000

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys. Journal of General Virology 84(Pt 12): 3253-3261, 2003

Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. Journal of Virology 76(3): 1089-1099, 2002

Field experiments with formalin-killed-virus vaccine against infectious bovine rhinotracheitis, bovine viral diarrhoea, and parainfluenza-3. American Journal of Veterinary Research 34(11): 1469-1471, 1973